MarketBeat
05 Aug 2026, 03:04 UTC · 6w ago
Verdict
Headline takes no side. We score SNDX +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Syndax forecasts peak annual U.S. net revenue for Revuforj to exceed $2 billion if it secures anticipated frontline AML indications.
So whatThis sets a massive long-term valuation target and high-growth trajectory for the company's primary asset.
More positive than 98% of claims this week
Total revenue for Q2 2026 grew 92% year-over-year to $72.8 million, driven by strong sales of Revuforj and Niktimvo.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 91% of claims this week
Syndax expects to report top-line results in Q4 from a Phase II trial of axatilimab (Niktimvo) in idiopathic pulmonary fibrosis and a Phase II study in frontline chronic GVHD.
More positive than 84% of claims this week
Revuforj is seeing expanded adoption in NPM1-mutated AML, with fewer than 15% of the 4,500 annual eligible patients having received a menin inhibitor to date.
So whatHigh untapped market penetration potential suggests a sustainable runway for near-term revenue growth.
More positive than 76% of claims this week
The company is developing new pipeline programs SNDX-4321 for lung cancer and SNDX-62122 for myelofibrosis, with IND submissions expected in 2026 and 2027 respectively.
More positive than 52% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Reported 92% revenue growth, strong sales growth for Revuforj and Niktimvo, and positive pipeline progress.
More positive than 73% of ticker scores this week
Benefiting from the strong commercial growth and adoption of Niktimvo, which generated $60 million in net sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2d ago
−7.7%
Price is moving against the score
$17.62 vs $19.08 close before publication (Aug 4) · not market-adjusted
SNDX chart →
